Navigation Links
Paclitaxel Plus Chemo Improves Outcomes in Early Breast Cancer
Date:5/27/2008

Study finds a trend toward better overall survival

TUESDAY, May 27 (HealthDay News) -- Adding paclitaxel to standard chemotherapy improved disease-free survival in women with early-stage breast cancer, a Spanish study finds.

The phase III trial included 1,246 women with early, non-metastatic breast cancer who were randomly assigned to receive treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC), or FEC followed by weekly paclitaxel (FEC-P).

The estimated five-year survival rate in the FEC-P group was 78.5 percent, compared to 72.1 percent in the FEC group. The study also found a trend toward improved overall survival, but it didn't reach statistical significance.

"Because distant relapse-free survival is usually associated with overall survival, a statistically significant benefit in overall survival may become evident with a more protracted follow-up," wrote Dr. Miguel Martin, of the Spanish Breast Cancer Research Group.

In a retrospective analysis of the data, the researchers weren't able to identify a subgroup of patients who were more likely to respond to paclitaxel therapy on the basis of their tumor's expression of the estrogen receptor and HER2.

The study was published in the May 27 online issue of the Journal of the National Cancer Institute.

In an accompanying editorial, researchers at Memorial Sloan-Kettering Cancer Center in New York City reviewed several trials that examined the effects of adding taxanes (a family of drugs that include paclitaxel) to existing adjuvant therapy for breast cancer.

In that regard, the study by the Spanish team is important, because it was well-designed and used a good regimen and schedule of drugs, noted Dr. Clifford Hudis and Dr. Chau Dang.

More information

The National Cancer Institute has more about breast cancer treatment.



-- Robert Preidt



SOURCE: Journal of the National Cancer Institute, news release, May 27, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
2. Chemotherapy may be culprit for fatigue in breast cancer survivors
3. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. To evade chemotherapy, some cancer cells mimic stem cells
5. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
6. PET scans can accurately detect a breast tumors response to chemotherapy
7. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
8. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
9. Medicare modernization act did not change chemotherapy as feared
10. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
11. Cancer conflict with chemotherapy treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Clearwater, FL (PRWEB) , ... March 27, 2017 ... ... accepts new patients for clear braces. People who want straight teeth without the ... Invisalign® in Clearwater, FL, without acquiring a referral. A custom-designed series ...
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... 3.0 was transitioned to the OSEHRA popHealth Community in 2014. It ... Work Group and the Developer Open Source Project Group. OSEHRA Organizational Member Zato ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon ... industry standards and specifications such as ANSI, ISO and proven test methods used ...
(Date:3/27/2017)... ... 27, 2017 , ... Advantexe Learning Solutions , a ... a new research study, The Business Readiness Report. The report explores the correlation ... the actual success of achieving individual and company goals. , There are ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the ... including all stages, is more than 95%. Once the cancer spreads to other organs, ... 30%. To find out how to avoid this latter group, tune in to ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of ... their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report provides an ... manufacturing and focuses both on contract manufacturers and cell therapy ... emerge as viable alternatives to conventional treatment options. ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 According ... Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators market ... million by 2022, growing at a CAGR of 3.6% during the forecast period. ... ... Allied Market Research Logo ...
(Date:3/24/2017)... Calif. , March 24, 2017 /PRNewswire/ ... epigenetics company, and Hamilton Robotics, Inc., who ... announced an ongoing collaboration that teams Zymo ... and RNA and DNA extraction products with ... already created optimized methods for microbiomics and ...
Breaking Medicine Technology: